Functional cure for hepatitis B in HIV/HBV co-infection
Treatments studied
Part of Digestive system, Immune system & allergy, Infections clinical trials.
This trial tests whether people with both HIV and hepatitis B can achieve a functional cure for hepatitis B. It aims to see if current treatment can be stopped safely after the hepatitis B virus is no longer active.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have both HIV and hepatitis B, with hepatitis B surface antigen (HBsAg) positive for at least 6 months.
- You have been on HIV treatment (ART) for at least 1 year and are still on it.
- Your hepatitis B virus level (HBV DNA) is very low - not detectable at a sensitive test.
- Your HIV is well-controlled with less than 20 copies/mL and your CD4 count is above 200 cells/μL.
- You do not have active hepatitis A, C, D, or E, serious liver disease, autoimmune disorders, cancer, or other major health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
This study tests a medicine called peginterferon alfa-2b to see if it can help children with chronic hepatitis B achieve a functional cure, meaning the virus stays under control. If your child has hepatitis B, this treatment might improve their chances of clearing the infection.
This trial tests a new combination of medicines to help your body control the hepatitis B virus without needing lifelong treatment. It aims for a 'functional cure,' which means the virus stays inactive and your liver stays healthy.
This study tests whether a combination of two drugs (ASC22 and Peg-IFN) can help people with chronic hepatitis B achieve a functional cure. The goal is to see if this therapy can clear the virus and improve liver health.
This study looks at whether extra treatment with peginterferon (a drug that boosts the immune system) can help lower the amount of hidden hepatitis B virus in the liver after you've already reached clinical cure. You'll have two liver biopsies to measure this, and the findings may help prevent the virus from coming back.
Hear when a new AIDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.